Page last updated: 2024-08-16

ribavirin and Glucose Metabolic Disorder

ribavirin has been researched along with Glucose Metabolic Disorder in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cariti, G; Ceretto, S; Ciancio, A; Ciccone, G; Colletta, C; De Blasi, T; Giordanino, C; Grasso, A; Marenco, S; Mazzucco, D; Picciotto, A; Pirisi, M; Rizzetto, M; Sacco, M; Saracco, G; Simondi, D; Smedile, A; Smirne, C; Traverso, A1
Craxì, A; Feld, JJ; Forton, D; Manns, MP; Negro, F; Sulkowski, MS1
Barreiro, P; Soriano, V; Tuma, P; Vispo, E1

Reviews

2 review(s) available for ribavirin and Glucose Metabolic Disorder

ArticleYear
Extrahepatic morbidity and mortality of chronic hepatitis C.
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Antiviral Agents; Cryoglobulinemia; Glomerulonephritis; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphoma; Morbidity; Ribavirin; Vasculitis

2015
[Role of tenofovir in HIV and hepatitis C virus coinfection].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir

2008

Other Studies

1 other study(ies) available for ribavirin and Glucose Metabolic Disorder

ArticleYear
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:1

    Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2014